Cargando…
STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations
Melanoma patients carrying an oncogenic NRAS mutation represent 20% of all cases and present worse survival, relapse rate and therapy response than patients with wild type NRAS or with BRAF mutations. Nevertheless, no efficient targeted therapy has emerged so far for this group of patients in compar...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016650/ https://www.ncbi.nlm.nih.gov/pubmed/31906480 http://dx.doi.org/10.3390/cancers12010119 |